Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Indivior Pharmaceuticals (INDV) stock in plain English

Free brief · no signupStart here
INDVPublished Nov 6, 2026
Indivior Pharmaceuticals Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Manufactures prescription treatments for substance use disorders and central nervous system conditions.
Assets:
Sublocade Depot FormulationMonthly buprenorphine injection generating 267 million dollars quarterly revenue
Suboxone Film PortfolioSublingual buprenorphine and naloxone strips for opioid dependence treatment
Hull Manufacturing PlantPrimary pharmaceutical formulation and production facility in the United Kingdom
Locked assetIn the full report
Checked Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

68
OPS ScoreOperating finances
Latest quote
-Quote unavailable
$6.07B
7.8×
$1.38B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 06, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was INDV. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Indivior Pharmaceuticals (INDV) do?

Indivior Pharmaceuticals Inc (INDV) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Manufactures prescription treatments for substance use disorders and central nervous system conditions. Formulates and distributes long-acting injectable and sublingual medications treating opioid use disorder and CNS. It is worth $6.07B on the market and sold $1.38B over the last year.

Market cap
$6.07B
P/E ratio
7.8×
Annual sales
$1.38B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 06, 2026

Brands and businesses behind INDV

  • Sublocade: Monthly extended-release buprenorphine injection that earns revenue from specialty distributor and clinic orders.
  • Suboxone: Sublingual film combining buprenorphine and naloxone earning revenue through retail pharmacy fills for opioid dependence.
  • Opvee: Nalmefene nasal spray generating sales from emergency medical services and law enforcement overdose response programs.
  • Perseris: Once-monthly subcutaneous injection generating sales from schizophrenia maintenance treatments prescribed by psychiatrists.

INDV’s flags, in plain English

Each flag is a number from Indivior Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 06, 2026.

Fat Margins

Profit margin of 32.8%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Wide Gross Margin

Gross margin of 85.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Runway Is Short

This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about INDV

How big is Indivior Pharmaceuticals?

Indivior Pharmaceuticals’ market cap is $6.07B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.38B: what customers paid the company over the last year, before any costs.

What is INDV’s P/E ratio?

INDV’s P/E ratio is 7.8×. Investors pay about 7.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with INDV?

State Medicaid budget cutbacks and shifting reimbursement formulas restrict patient coverage for premium injectable therapies. That is one risk on Indivior Pharmaceuticals’ card. Its first risk flag is Runway Is Short, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Indivior Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. INDV’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card